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The overall aim of the PhD thesis was to investigate different aspects of treatment with sacral 
neuromodulation (SNM) and injection of bulking agents (Permacol®) for faecal incontinence 
(FI) and concomitant pelvic floor dysfunction in women with a history of obstetric anal 
sphincter injuries (OASIS). 
Method	
Consecutive women with severe FI following OASIS after failure of conservative treatment 
were eligible. All women went through a three-week percutaneous nerve evaluation (PNE) 
period. The women with a successful PNE, defined as 50 % reduction of weekly FI episodes, 
were randomly assigned to SNM or Permacol®(1:1). After 6 months, cross over to the other 
treatment arm were allowed. Baseline factors related to PNE outcome is discussed in paper I. 
The changes from baseline to 6 months between the SNM group and Permacol® group are 
analysed in paper II. Outcomes were evaluated with questionnaires for FI (St Mark’s score, 
bowel habit diary), Quality of life (QoL), (Rockwood FIQL, EQ-5D), urinary incontinence 
(UI) (ICIQ-UI-SF) and sexual function (RooS). The outcome after SNM in women with 
combined FI and UI (double incontinence, DI) is explored in paper III.  
Main	results		
Fifty-six of the 63 (89%) women had a successful PNE. Efficacy was related to concomitant 
UI (p=0.046) and body mass index (BMI) (p=0.03). Pain during PNE was related to 
unsuccessful outcome (p=0.046). The extent of sphincter defect was unrelated to efficacy (p= 
0.1). The reduction in the St. Mark’s score between baseline and 6 months was 11.2 (SD 5.3) 
in the SNM group (n=30) versus 2.3 (SD 5.0) in the Permacol® group (n=26),	resulting	in	a	
difference of 8.9 (95% CI 6.1-11.7, p<0.0001) in favour of SNM. UI ceased in 13 (33%) and 
weekly FI episodes disappeared in 23 (62%) of the 37 women treated with SNM for DI. The 
reduction in ICIQ-UI-SF score was 5.8 (95% CI 3.7-8.0, p<0.001) and in the St Mark’s score 
was 10.6 (95% CI 8.6-12.7, p<0.001). 
Conclusion	
SNM was superior to Permacol® in terms of change in St Mark’s score and disease specific 
QoL. Concomitant UI was successfully treated with SNM in the majority of the women with 
DI. Outcome was not related to the extent of a pre-existing sphincter defect. 
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NORWEGIAN	SUMMARY	
Det overordnete formålet med studien var å undersøke behandling av alvorlig 
avføringslekkasje med sakralnervemodulering (SNM) og injeksjon av en romoppfyllende 
substans (Permacol®) i slimhinnen like innenfor lukkemuskelen. Kvinner med alvorlig 
avføringslekkasje på bakgrunn av rift i lukkemuskelen i forbindelse med fødsel var aktuelle 
for studien.  
 
Fra 2012-2014 gjennomgikk 63 kvinner en tre ukers testfase med perkutan nerve-evaluering 
(PNE). De 56 med effekt under PNE ble videre randomisert til enten SNM eller Permacol®. 
Effekten på avføringslekkasje, målt med reduksjon i St marks inkontinens-score (0=ingen 
lekkasje, 24=komplett lekkasje) ble sammenlignet mellom gruppene. Etter 6 måneders fikk de 
uten effekt tilbud om den andre behandlingen.   
 
I den første artikkelen viste vi at de 56 (89%) kvinnene med effekt under PNE i større grad 
rapporterte ledsagende urinlekkasje (dobbelinkontinens) sammenlignet med de uten effekt. De 
hadde i tillegg høyere kroppsmasse-indeks (BMI). De som opplevde smerter under PNE 
hadde derimot dårligere effekt. Det var ingen sammenheng mellom effekt og omfanget av 
lukkemuskelskaden vurdert med ultralyd. I den randomiserte studien fant vi at effekten på 
avføringslekkasje, urinlekkasje og livskvalitet var høysignifikant i SNM-gruppen (n=30) 
sammenlignet med en beskjeden reduksjon i Permacol®-gruppen (n=26). Forskjell i St Marks 
score var 8.9 (95% CI 6.1-11.7, p<0.0001).  I den siste studien undersøkte vi 37 kvinner med 
dobbelinkontinens ett år etter behandling med SNM. Totalt 13 (33%) ble kurert for 
urinlekkasje og 23 (62%) for avføringslekkasje. I tillegg fant vi en høysignifikant bedring av 
både urin score (5.8, 95% CI 3.7-8.0, p<0.001) og St Marks inkontinens score (10.6, 95% CI 
8.6-12.7, p<0.001).  
 
Som konklusjon var SNM overlegen Permacol® i behandlingen av avføringslekkasje på 
bakgrunn av rift i lukkemuskelen i forbindelse med fødsel. Dobbelinkontinens ble vellykket 
behandlet med SNM i motsetning til Permacol. Effekt av SNM var ikke relatert til omfanget 








AI   Anal incontinence  
BMI   Body mass index 
CI   Confidence interval 
CONSORT Consolidated Standards of Reporting Trials  
DI  Double incontinence 
EAS  External anal sphincter 
EAUS  Endoanal ultrasonography 
ENS  Enteric nervous system 
EPG  External pulse generator (Verify) 
EQ-5D™-3L The Euroqual 5- dimension 3-level  
FI  Faecal incontinence 
FIQL   Faecal incontinence quality of life scale  
IAS  Internal anal sphincter 
ICIQ-UI-SF  International Consultation on Incontinence Questionnaire for Urinary 
Incontinence- Short Form  
ICS International Continence Society 
IPG  Internal pulse generator (Interstim 2) 
IQR   Interquartile range 
OASIS   Obstetric Anal Sphincter Injuries 
PNE  Percutaneous Nerve Evaluation 
PRM   Puborectalis muscles  
QoL  Quality of life 
RAIR   The rectoanal inhibititory reflex  
RCT   Randomized controlled trial 
SD  Standard deviation 
SNM  Sacral Neuromodulation 
UI  Urinary Incontinence 
UNN   University Hospital of North Norway 
2D   Two-dimensional 

















The father of science, Aristotle, was born in 384 BC. His mother Phaestis died young and his 
father Nicomachus, who was the personal physician to the king Amyntas III of Macedonia, 
raised him. Medical skills were kept secret and handed from father to son. Nicomachus died 
when Aristotle was only 10 years old and for that reason he could not succeed his father. 
Instead, he became a student at Plato´s Academy. Contrary to his teacher Plato, Aristotle 
claimed that theories had to be modified or discarded based on observations and facts. 






Figure 1 The father of science, Aristotle (384-323 BC). The first clinical trial was published in 1747 
and the first RCT in 1948 
 
 
The first clinical study we are aware of was conducted in 1747 after the Scottish physician 
James Lind (1716-1794) hypothesized that citrus fruits could cure scurvy. He divided 12 men 
suffering from scurvy at a ship into six groups, adding different nutrition to their diet. Those 
who received citrus fruits recovered. In 1948, Sir Austin Bradford Hill published the first 
study with methodological elements of a randomized controlled trial (RCT), aiming to 
determine the effect of streptomycin on pulmonary tuberculosis[2].  
 
Evidence- based medicine describes a systematic approach to analyse published research and 
was in 1996 defined as  “the conscientious and judicious use of current best evidence from 
clinical care research in the management of individual patients”[3, 4]. RCTs are considered 
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the gold standard for a clinical trial and generate evidence of the highest level when correctly 
conducted. The CONSORT guidelines were established in 1996 to improve and standardize 
conduction and reporting of RCTs [5].  
 
Although RCTs are the gold standards, RCTs have limitations related to the complexity of 
medicine and surgery. Each patient and operation is unique despite standardisation and strict 
protocols, blinding of both the patients and surgeons are challenging to accomplish and 
surgical procedures are skill-dependant and constantly developing [6]. 
 
These limitations are clearly demonstrated when conducting RCTs on the treatment for 
complex pelvic floor dysfunction affecting several pelvic compartments with a wide range of 
clinical problems with major impact on quality of life (QoL), including faecal incontinence 
(FI), urinary incontinence (UI) and sexual dysfunction[7-9]. The aetiology is multifactorial 
and treatment often requires multiple specialists [10]. There is lack of international consensus 
on definition, classification and outcome reporting[11]. The evidence base is poor and women 
with a recognized sphincter defect have generally been excluded from the few existing 
randomized trials [7, 12, 13]. Uncertainty persists as to the optimal choice of treatment 
strategy for FI and concomitant pelvic floor dysfunction after obstetric anal sphincter injuries 















Continence is a highly complex physiological function requiring structural and neuro-
hormonal integrity. Coordination of the anus, rectum, colon and pelvic floor is essential, in 
addition to adequate cognitive function and acquired mobility to be able to access a toilet. 
Factors important for continence are listed in Table 1. FI occurs if one or more of the factors 










Anal sphincter complex 
 
Internal anal sphincter 
Sympatic nerves (hypogastricus) 
Enteric nervous system  
Resting anal pressure  
Sampling reflex 
External anal sphincter Pudendal nerve Voluntary squeeze pressure 
Anal cushions Afferent parasympathetic  Anal sensation 
 
Rectum 
Sympathetic nerves Relaxation 
Parasympathetic nerves Contraction 
Enteric nervous system Sampling reflex 
 
Colon 
Sympathetic nerves Relaxation 
Parasympathetic nerves Contraction 
Enteric nervous system Peristaltsis 
 
Small Intestine 
Sympathetic nerves Relaxation 
Parasympathetic nerves Contraction 
Enteric nervous system Peristaltsis 
Pelvic floor 
Puborectalis muscle 
Somatic sacral nerves (S2-S4) 
 
Maintenance of anorectal angle 
 
Other  
Central nervous system  
Peripheral nervous system  
Cognitive function  
Mobility 
 
Table 1 Factors important for faecal continence.  
 
The	anorectum	
The anal canal is approximately 2-4 cm long and surrounded by the anal sphincter complex 
involving the internal (IAS) and external anal sphincter (EAS) (Figure 2a). The IAS is a 
thickened extension of the circular smooth muscle of the rectum (0.3-0.5 cm). Its action is 
entirely involuntary, innervated by sympathetic (superior rectal and hypogastric plexus, L5) 
and parasympathetic nerves (nn pelvici/s2-s4) via extensions of the enteric nervous system. 
The main function of IAS is to maintain continence during rest. IAS accounts for 55-85% of 
the resting pressure, the state of contraction that keeps the anal canal closed. EAS contributes 
with 15-30% to the resting pressure, while another 15% is caused by anal cushions, which are 








Figure 2 a) The anatomy of the anal canal with the anal sphincter complex consisting of the internal 
anal sphincter (IAS) and external anal sphincter (EAS) b) The tonic active puborectalis muscle (PRM) 




The EAS is striated muscle responsible for the voluntary anal squeeze. Motor and sensory 
nerves from the inferior rectal branch of the pudendal nerve (S2-S4) innervate the EAS. EAS 
continues into the levator ani, a musculotendinous sheet divided into the iliococcygeus, 
ischiococcygeus and pubococcygeous, which is further subdivided into the pubourethralis, 
pubovaginalis and puborectalis muscles (PRM), the last in close relationship to the EAS [21, 
22]. The PRM is probably innervated directly by ipsilaterally branches from the sacral plexus 
(S3 and S4), not the pudendal nerve [18]. The tonic active PRM also contributes to continence 
by maintaining the anorectal angle (figure 2b) [19]. The rectum is an elastic reservoir for stool 
and is autonomic innervated by parasympathetic nerves from the sacral plexus S2-S4 and 
sympathetic branches from the mesenteric plexus, forming the rectal plexus [19] 
Defecation	
The first part of defecation is involuntary and triggered by reflexes. The rectum is normally 
empty. Rectal distension initiates a reflectory relaxation of IAS and decrease in the resting 
anal pressure, the rectoanal inhibititory reflex (RAIR). This reflex is contained in the enteric 
nervouos system (ENS) and mediated by nitric oxid. Simultaneously EAS contracts (rectoanal 
contractile reflex) to augment the resting anal pressure to preserve continence.  Rectal 
distension also increases peristaltic of colon via the intrinsic nerves (enteric ns). The sampling 
reflex, with transient relaxation of the IAS, allows the rectal content to interact with the 
sensitive epithelial lining in the upper part of the anal canal, facilitating the fine-tuning of the 
continence barrier by distinguishing between stool and gas[18, 19, 23].  
 
The second part of defecation is voluntary and dependent on the desire to defecate with 
voluntarily relaxation of the EAS and pelvic floor muscle. The anorectal angle increases, with 
descent of the pelvic floor and evacuation of rectal content[19, 24]. If defecation is not 
socially convenient, voluntary contraction of EAS and PRM decrease the anorectal angle. The 
rectal content is forced back in the rectal reservoir, allowing the IAS again to contract raising 
the resting pressure and maintaining continence. The amplitude and duration of the RAIR 
increases with the volume of rectal distension. The voluntary defecation response is also 
regulated by the central nerves system, but the mechanism is still poorly understood [18, 19, 
25]. Impaired rectal compliance can occur after radiation proctitis or inflammatory bowel 





Management of FI is a neglected field within health care and surgery. The affected women 




The definition of FI is inconsistent and international consensus is lacking [18, 26]. The 
International Continence Society (ICS) and the International Urogynecology Association have 
defined FI as involuntary loss of liquid or solid stool, whereas anal incontinence (AI) has been 
defined as loss of faeces or flatus [27]. Urgency FI is defined as FI associated with a sudden 
compelling desire to defecate, difficult to defer. Passive FI is defined as FI without warning 
[27]. Instead of FI, the patients prefer the term accidental bowel leakage [17, 28]. 
 
Prevalence		
The true prevalence of FI is not known because the subject is taboo with patients 
underreporting symptoms, but health professionals are also reluctant to address the subject 
[18, 29]. The estimated median prevalence from a recent systematic review was 7.7 % in the 
general adult population including both men and women older than 18 years, with increasing 
prevalence with increasing age [30]. The median prevalence in women was 8.9 % compared 
to 8.1 in men [30]. In a Norwegian survey on FI in women, 19.1% reported AI and 3.0% FI 
[31]. The prevalence following OASIS is estimated to 15-61%, and increasing with age [7, 8]. 
 
Risk	factors		
A risk factor can be defined as a factor that places the exposed at greater risk for developing 
the disease compared with the non-exposed. Anorectal dysfunction leading to FI is caused by 
a variety of conditions. More than one mechanism may contribute to development of FI and 
the aetiology is often multifactorial. Despite the basic understanding of FI, there are still 
unknown factors in the pathogenesis. Epidemiological studies on risk factors for FI are mainly 
based on retrospective studies [18, 23]. 
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Common risk factors for FI include advanced age, lifestyle, colorectal and anal disorders, 
childbirth and OASIS, UI, systemic diseases and neurological disorders [10, 14, 23, 30, 32]. 




Anal sphincter complex 
Injury (OASIS, anorectal surgery, trauma), perianal abscess, infection and fistula, 
fissures, haemorrhoids, anal carcinoma 
 
Rectal 
Proctitis (radiation, inflammatory bowel disease), Infection, colorectal cancer, rectal 
prolapse or intussusception 
Pelvic floor   Injury or trauma to muscles and nerves (OASIS, vaginal delivery) 
Pudendal nerve Obstetric or traumatic injuries, chronic straining, pelvic organ prolapse 
 
Small intestine and Colon  
GI infection, inflammatory bowel disease, colorectal cancer, food intolerance, Irritable 
bowel syndrome, constipation and diarrheal, malabsorption 
NEUROLOGICAL 
DISEASES  
Cerebrovascular disease, spinal cord trauma and neurological disorders such as 
Parkinsons disease and Multiple Sclerosis 
SYSTEMIC DISORDERS  Diabetes Mellitus, sclerodermi, metabolic disorders 
 
CONGENITAL 
Anorectal anomalies (imperforate anus, rectal agenesi, cloacal agenesis), spina bifida and 




Drugs (anticholinergic, laxatives, opioids, antidepressants, caffeine, muscles relaxants) 
 
Table 2 Risk factors for faecal incontinence. OASIS= Obstetric anal sphincter injuries  
 
Obstetric	anal	sphincter	injuries		
Pregnancy, childbirth and OASIS are the main risk factors associated with FI in women. 
OASIS, classified according to Sultan et al [33], occurs in 0.5%-7.0% of vaginal deliveries. In 
addition, occult anal sphincter defects have been documented in approximately 30% of 
multiparous women[7, 33-35]. The reported prevalence of FI following OASIS is between 
15% and 61% [7, 8, 10], with a twofold-increased risk of FI compared with the non-exposed 
[36]. Inadequate repair of OASIS and occult defects may contribute to late onset of 
symptoms, given the median age of symptom debut is 55 years, two to three decades after the 
vaginal delivery [8, 22, 23, 33, 37]. Injuries to the pudendal nerve can also occur by stretching 
or compression during vaginal delivery [8, 10]. The relationship between the extent of 
sphincter defect and clinical symptoms is, however, controversial, and the sphincter 
disruption is only one factor in the complexity of FI [38]. One hypothesis is that OASIS 
represents the “initial” of “multiple hits”[39, 40].  
 
Evaluation		
Existing guidelines do not define when specific testing should be performed in the evaluation 
of FI [12, 18, 31]. Evaluation of women with FI involves a medical history aiming to identify 
risk factors, severity of symptoms, their impact on QoL and need for treatment. Symptom 
severity and disease-specific QoL can be quantified by validated questionnaires such as the St 
Mark’s score and the Rockwood score[41-43]. Stool consistency can be characterized by stool 
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scales such as the Bristol scale [44]. Physical examination and endoanal ultrasound (EAUS) is 
mandatory before considering surgery. Colonoscopy may be indicated to exclude colorectal 
pathology, while anorectal manometry is indicated in selected patients.  
 
Physical	Examination	
Clinical inspection and digital examination of the anal canal, rectum and vagina provides 
information of the thickness of the perineum and perineal body, the ano-rectovaginal septum, 
estimation of anal sphincter muscles thickness anteriorly in addition to resting tone and 
sphincter squeeze. The anal and rectal mucosa is further examined with a proctoscop.  
 
Endoanal	ultrasound		
The structural integrity and morphology of the anal sphincter complex can be assessed with 
two-dimensional (2D) and three-dimensional (3D) EAUS. Volumetric endovaginal ultrasound 
and transperineal ultrasound have been proposed as alternative imaging modalities to describe 
anal sphincter integrity [10]. Opposed to 2D EAUS, the 3D images enable visualization from 
different angles and enables classification of the radial and longitudinal extent of a defect, 
allowing differentiation between EAS and adjacent muscles and better visualization of 
defects[8]. Further advantages are the possibility to perform offline analysis because the 
images can be stored digitally and reviewed on a personal computer.[45]. 
 
Ultrasonography is based on the principles that the ultrasound waves are being reflected or 
transmitted when traversing the tissue (echogenicity). The reflected ultrasound waves form 
the images seen on the screen. Structures are characterized as hyperechoic (white on the 
screen, brighter) or hypoechoic (gray on the screen, darker). The IAS is hypoechoic and easily 
identified, and becomes thicker with age. Defects of the IAS are recognized as 
discontinuation of the hypoechoic ring. The EAS and striated muscles have a hyperechoic or 
mixed echogenicity and can be more difficult to separate from adjacent structures. The EAS 
in women forms an incomplete ring in the upper one third of the anal canal at the 12-o´clock 
position, and this finding must not be interpreted as a defect[45]. The EAS volume decreases 
with age. Muscular fibres are replaced with granulation tissue and fibrosis after injuries to the 
EAS, and defects typically present as hypoechoic areas [8, 21, 46].  
 
The relationship between a sphincter defect on EAUS and the severity of FI is uncertain [45, 
47]. Nevertheless, it has been confirmed by histology that EAS defects revealed at EAUS in 
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patients with FI represent true defects, implying that EAUS is important in the assessment of 
FI [48]. Because of the limitations related to interpretation of EAUS, a Cochrane review 
recommends caution when considering exclusion from trials based on EAUS defects [14]. 
 
Anorectal	physiological	testing		
Anorectal physiological testing complements examination and structural information from 
EAUS in the evaluation of FI includes anal manometry, anal and rectal sensation, compliance, 
testing of reflexes and pudendal nerve terminal motor latency-test (PNTML). Although 
frequently used in research, anorectal physiological testing has many limitations with a wide 
range of normal values and poor correlation to severity of symptoms or change after 
treatment. Evaluation with anorectal physiological testing was not included in the studies, 
because it previously has failed to provide clinically useful information in the treatment of FI 
with SNM or bulking injectables [8, 10, 14, 16, 38, 45, 49-51].  
 
Anal	manometry	
Anal manometry describes the pressure of the anal sphincter complex during rest and changes 
in the anal pressure during voluntary squeeze [52].  The resting pressure describes the state of 
contraction that keeps the anal canal closed at rest, and predominantly represents IAS 
function. Maximal resting anal pressure (RAP) is defined as the difference between intrarectal 
pressure and the highest recorded anal sphincter pressure at rest. The voluntary squeeze 
pressure primarily represents EAS function. Maximum Anal Pressure is defined as the 
difference between the intrarectal pressure and the highest pressure that is recorded at any 
level within the anal canal during the squeeze. Functional anal canal length is defined as the 
length over which resting pressure exceeds the rectum pressure[25] . IAS insufficiency is 
characterized by lower resting pressure whereas EAS insufficiency typically is associated 
with lower squeeze pressure [25, 52, 53].   
 
Rectal	sensation	and	compliance	
Rectal sensation test is performed by distending a balloon in the rectum. The lowest volume 
that evokes sensation (rectal sensory threshold), the volume that evokes the urge to defecate 
and the maximum tolerable volume with sensation of pain are measured.  The rectal 
compliance is the relationship between change in intrarectal pressure during volume 
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distension and reflects rectal capacity and distensability [25]. Rectal hypersensitivity can be 
related to urgency and EAS defects[33].  
 
Anorectal	Reflex	Activity	
A rapid distension of the rectum induces a transient increase in rectal pressure, followed by 
transient increase in anal pressure associated with EAS contraction (the rectoanal contractile 
reflex) and a prolonged reduction in anal pressure due to a relaxation of the internal anal 
sphincter (RAIR). The reflex (RAIR) indicates a normal nervous interaction between the 
rectum and the anal canal. The reflex is absent in patients with Hirschsprung’s disease[25].  
 
Pudendal	nerve	terminal	motor	latency-test		
Pudendal nerve terminal motor latency-test (PNTML) evaluates the time from stimulation of 
the pudendal nerve at the ischial spine to a recordable muscle contraction in the levator ani/ 
EAS. A prolonged PNTML-test indicates pudendal neuropathy. The test has poor intra- and 
inter-observer reproducibility and evaluates a compound muscle action potential, not only 




The aim of any treatment of FI should be to restore continence and improve QoL. The main 
approaches are currently conservative management, neuromodulation and reconstructive 
surgery including implants and prosthesis that augment the sphincter function, and finally the 
creation of a stoma. So far, reconstructive surgery has not been shown to provide consistent, 
long-term effectiveness without complications[14, 38, 50]. If conservative treatment fails, 
sacral neuromodulation (SNM) is considered first line treatment, followed by individual 
evaluation and patients’ preferences. However, international guidelines are inconsistent 
regarding the role of SNM versus secondary sphincter repair if the anal sphincter complex is 
disrupted [31, 55].  
 
Conservative	treatment	
Conservative management includes use of diet with fibre supplements and medication to 
regulate stool consistency and frequency, which affects severity of FI.  Loperamide 
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(Imodium®) is a synthetic opioid that increases the transit time and the anal sphincter resting 
tone and improves rectal sensitivity. Loperamid has been shown to reduce urgency and FI 
episodes [56]. 
 
Pelvic floor muscle exercises including biofeedback are thought to improve FI symptoms by 
augmenting sensation and contraction of the pelvic floor muscles. Treatment with 
biofeedback is performed with an EMG probe inserted into the anorectum, providing 
feedback to the user during the squeeze. The effectiveness of both biofeedback and pelvic 
floor exercises is however controversial. No studies have reported significant differences of 
biofeedback or pelvic muscle exercises compared to other conservative treatments for FI. It 
has been believed that biofeedback and pelvic floor exercises improve rectal sensation, but the 
evidence are lacking [57, 58].  
 
Patients can also be taught behavioural techniques such as scheduled toileting, use of 
supportive devices like absorbent padding and plugs [59], and assisted bowel evacuation such 
as enema and transanal irrigation [60].  
 
Sacral	neuromodulation		
SNM was first described in 1995 by Matzel, proposing the idea that low-voltage electrical 
stimulation of the sacral spinal nerves had the potential to recruit residual function of pelvic 
organs and modify the complex neuromuscular function required for defecation [61, 62]. 
SNM involves stimulation of the sacral nerve roots (S3 or S4) by an quadripolar electrode 
lead system connected to an subcutaneous implanted pulse generator (IPG, InterStim® 
Therapy, Medtronic, Inc., Minneapolis, US, Figure 3) [38].  
 
One advantage of SNM is the staged procedure in which patients with a successful 
percutaneous nerve evaluation (PNE) are selected for permanent implantation, allowing the 
patient to test the treatment before definitive implantation of the permanent IPG. Substantial 
improvement during PNE predicts a successful long-term outcome of SNM [63-65].  The 
success-rates of SNM evaluated by a per protocol analysis in the mid- and long-term have 
been shown to be 80% based on a greater than 50% reduction in FI episodes, but only 60% 




Figure 3 Sacral neuromodulation involves placement of an quadripolar electrode lead system in the 
S3 or S4 root, which is connected to an internal pulse generator (IPG, InterStim® Therapy, 
Medtronic, Inc., Minneapolis, US) in the subcutaneous fat of the buttock[38].”Reproduced with 
permission of Medtronic, Inc.” 
 
Injectable	bulking	agents		
The concept of injection of bulking agents is to produce a bulk in the submucosa or in the 
intersphincteric space to close the anal canal by enhancing the anal cushions, thereby 
preventing FI [51].  There is no consensus on material, volume or location where the agent 
should be placed, with expanding indications[66, 67]. Bulking agents has been shown to 
improve FI in several series and randomized trials[67-70], but the clinical implication of the 
treatment has been questioned [51]. 
 
Other	surgical	treatment	for	FI	
Secondary sphincter repair is still indicated if investigation reveals a large defect or a cloacae, 
but the number of procedures has decreased with implementation of SNM and the 
deterioration of function 10 years after surgery [14]. For other surgical procedures like the 
artificial bowel sphincters and electro-stimulated graciloplasty, a Cochrane review concluded 
that it is uncertain whether surgical intervention does more good than non-surgical treatment 
[14]. Other innovative and promising treatments are the Gatekeeper™, the Sphinkeeper™ [71, 
72] and the magnetic sphincter prosthesis [73, 74].  Ultimately a permanent stoma may be the 





FI occurs rarely as an isolated pelvic floor dysfunction in women. Pelvic floor dysfunction 
consists of a wide range of clinical problems including UI, sexual dysfunction, pelvic organ 
prolapse and chronic pelvic pain in addition to FI [7-9]. FI with concomitant UI, referred to as 
double incontinence (DI) is reported in 30-50 % depending on the population studied [76, 77]. 
Female sexual dysfunction is probably present in more than 30 % [7, 77, 78]. FI, UI and 
sexual dysfunction are all distressing health problems leading to physical, psychological, and 
social disability [7-9, 79]. 
 
Vaginal birth is the main risk factor for pelvic floor dysfunctions and traumatic vaginal 
delivery contribute to complex damage to the pelvic floor with stretching of the pelvic floor 
muscles, endopelvic fascia and nerves [22]. Similar to FI, the aetiology is multifactorial and 
associated with OASIS and ageing with progressive neuropathy, lack of fascial support, 
hormonal changes and functional limitations [10, 22, 32, 80]. For DI in particular, depression 
and neurological diseases has been identified as risk factors [81]. The association between 
depression and pelvic floor dysfunction could be explained as a consequence of the disease-
burden, but a dysfunction in neurotransmitters has also been suggested to contribute to DI 
[81]. The presence of crossed reflexes between the bladder, urethra and anorectum could 
explain some of the association between UI and FI [82]. Since SNM has the potential to 
restore both urinary and faecal continence by modification of nerve activity, SNM has been 
suggested as a viable treatment option for DI if conservative treatment fails [12, 62].   
 
The complex nature of pelvic floor dysfunctions may require assessment by multiple 
specialists such as surgeons, uro-gynaecologists, urologists, radiologists, specialist nurses, 











The overall aim of the PhD thesis was to investigate SNM and injection of bulking with 
Permacol® for FI and concomitant pelvic floor dysfunction in women with a history of 
OASIS.  
 
Some clinical questions and observations formed the basis for the hypotheses and design of 
the study protocol in 2011. The first question was whether the effectiveness of Permacol® 
was comparable to SNM in women with FI following OASIS. The use of bulking agents 
became widespread due to their simplicity and suggested cost-effectiveness compared with 
SNM [83]. SNM and injection of bulking agents had not been compared in a randomized 
controlled trial, and uncertainty persisted about the optimal choice of treatment for 
postobstetrical FI, and a comparison between the two minimally invasive treatments was 
warranted [12-16]. The comparison between the two treatments was presented in paper II.  
 
The second question was whether the effectiveness of SNM or bulking injectables for FI 
following OASIS was related to the extent of the pre-existing sphincter defect. Both the 
European bowel study group [84] and a review [85] emphasized the poor quality of the few 
published studies and the need for well-designed prospective studies. The correlation between 
effectiveness and extent of the sphincter defect was analysed in paper I-III.   
 
The systematic use of questionnaires for assessment of pelvic floor dysfunction in the pelvic 
floor unit revealed a high prevalence of concomitant UI. The third question was whether 
concomitant UI and pelvic floor dysfunction was treated effectively with SNM. This question 








The purpose of the first study was to assess efficacy during the three-week PNE using the 
tined lead and the Verify® external pulse generator (EPG) in patients with FI and a history of 




The purpose of the second trial was to compare the effectiveness of SNM with injection of 
bulking with collagen (Permacol®) in women with FI following OASIS. 
 
Aim	paper	III	
The purpose of the third study was to investigate the effectiveness of SNM for combined UI 







The study design included prospective collection of data in consecutive patients with FI and a 
history of OASIS. Figure 4 illustrates the study design from assessment of eligibility to 12 
months follow up and paper I-III related to the entire study population. The study was 









































































































All the papers involved women with severe FI following OASIS, representing the largest 
subgroup of patients with FI [14]. The patients were recruited from the outpatient clinic at the 
tertiary colorectal referral centre at UNN and St Olavs hospital, Trondheim, after failure of 
conservative treatment.   
 
Substantial FI was defined as St Mark’s incontinence score of more than 8, and weekly FI 
episodes of loose or solid stool despite optimal conservative management. An international 
consensus and a clear definition of severe FI and successful treatment of FI is lacking[11].  A 
weekly FI episode is a common applied inclusion criterion for SNM[49], with 50 % reduction 
of weekly FI episodes as definition of success,  but has been criticized as a outcome measure 
for treatment for FI[11].  The St Mark’s score has been shown to correlate to QoL in women 
with a history of OASIS [86] and a score grater than 8 has been shown to be associated with 
deteriorated QoL [87]. Therefore, a cut of value of 8 of the St Mark’s score in addition to 
weekly FI episodes was used as the definition of severe FI. 
 
Conservative treatment included at least 6 months tailored management with supportive 
devices, including paddings and plugs, dietary modification, constipating medication, pelvic 
floor exercises with or without biofeedback and trans-anal irrigation.  Tailored conservative 
treatment was initiated at the outpatient clinic and monitored by specialized nurses affiliated 
at the National Advisory Board of Continence and Pelvic Floor Health of Norway, UNN.   
 
OASIS was defined as a third- or fourth-degree perineal tear during childbirth [35]. Because 
the women were referred from hospitals throughout Norway, information regarding the 
OASIS and primary repair was incomplete. Women with FI and a history of OASIS were 
eligible for inclusion regardless whether a sphincter defect was revealed at EAUS or not. No 
upper limits of the extent of sphincter defects were defined.  All eligible women were 
considered for enrolment in the trial and not for secondary sphincter repair.  The exception 
was the presence of a cloaca, which would require reconstructive surgery for other reasons 
















Faecal incontinence with St. Mark’s score > 8 and 




Failed conservative treatment (dietary modification 
or constipating medication, pelvic floor exercises 
with or without biofeedback, supportive devices such 
as pads, plugs, and trans anal irrigation) 
 
Previous major pelvic surgery including irradiation 





Untreated rectal external prolapse 
 
18 years or older 
 
Untreated perianal fistula 
  
Active Inflammatory Bowel Disease (IBD) 
 




This study included all the women with FI following OASIS enrolled at UNN who underwent 
a three-week PNE. The patients from St Olav Hospital were excluded because the 3D EAUS 
datasets were unavailable. 
 
Inclusion	and	exclusion	criteria	paper	II	
The women with FI and a history of OASIS who had a successful PNE were randomized, 
because a successful PNE is a prerequisite for definitive implantation of an IPG [55]. Patients 
were recruited from both St Olav Hospital and UNN. 
 
Inclusion	and	exclusion	criteria	paper	III	
The third study included the women with combined UI and FI that received SNM. In addition 
to the eligible women randomly allocated to SNM, the women primarily assigned to 
Permacol® and who crossed over to SNM after 6 months, were included (Figure 1). UI was 
defined as concomitant if ICIQ-UI-SF score was one or greater. Women with isolated FI and 






All the patients were invited to participate in group-conversations the day before surgery with 
6 to 8 patients according to hospital practice. An experienced nurse led the group-
conversations and the surgeons were available for answering questions. Information about the 
treatment and the postoperative period were given and the patients had the opportunity to 
share experiences and questions. 
 
The PNE procedure was performed with local anaesthetic in combination with monitored 
sedation. Intravenously antibiotic prophylaxis with Cefuroxim was administrated 
preoperative. The same team with one surgeon performed all procedures. The surgical 
procedure was standardized using a tined lead and the straight stylet (3093, Medtronic, 
Minneapolis, Minnesota, USA). The tined lead was placed through the S3 or S4 foramina 
using Seldinger’s technique and fluoroscopy. According to recommendations [88], the tined 
lead was positioned to achieve a low-threshold motor response on as many of the four 
electrodes as possible. The tined lead was connected to an EPG (Verify® model 3531, 
Medtronic) by an extension wire. Three programs eliciting a low-threshold sensory response, 
with best response defined as sensation nearest to the anus, were established in the operating 
room. The EPG was turned on and the response controlled after the patients had recovered 
from the anaesthesia. 
 
Patients were discharged after learning to adjust stimulation with the patient controller (Model 
3537, Medtronic). Participants were offered sick leave for the entire 3-week PNE period and 
were followed by weekly phone calls according to hospital routine. Instructions for 
readjustment, including change of amplitude, were repeated to patients who reported 
suboptimal response or painful stimulation.  
 
The extension wire was cut at skin level by the general practitioner after three weeks, 
terminating the PNE period. Cutting the extension wire at skin level after the PNE period has 
been a part of the routines since the tined lead was introduced to the standard PNE procedure 
as an alternative to the temporary lead in 2008. In patients who had a successful PNE, the 
tined lead was left in place for definitive implantation, usually two to four weeks after 
terminating the PNE. For women assigned to SNM, the tined lead was connected to an IPG 
(Interstim II 3058 Medtronic, Minneapolis, MN, USA) and placed in a subcutaneous pocket 
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(Figure 5). The procedure was performed in local anaesthesia in combination with monitored 
sedation. Intravenously antibiotic prophylaxis with Cefuroxim was administrated preoperative 
in combination with an implant impregnated with gentamicin (Collatamp®). The same 
procedure was performed in the women who were primarily assigned to injection of 
Permacol®, but crossed over to receiving delayed implantation of SNM after 6 months follow 
As for the EPG, the IPG was programmed to elicit a low-threshold perianal sensory response.  
 
All of the patients received a patient programmer (ICon® 3037, Medtronic, Minneapolis, 
MN, USA) allowing adjustments or turning the stimulation on and off. The IPG was 
reprogrammed at the prescheduled follow-ups at 3 and 6 months in case of adverse events 
such as painful stimulation, deterioration of urinary function or persisting weekly FI episodes. 












Cross-linked porcine dermal collagen, Permacol® (Tissue Science Laboratories, Aldershot, 
Hampshire, UK) was used as a bulking agent. The procedure was performed at the outpatient 
clinic, without anaesthesia or bowel preparation. Antibiotic prophylaxis (Ciprofloxacin 500 
mg x2) was given orally. Two surgeons performed all the procedure (MR, TD). The 
Permacol® injectable bulking agent was delivered in two attached syringes, one empty and 
one prefilled containing Permacol®. By passing the solution back and forth between the two 
syringes about 20 times, an adequate mixture for injection was achieved. In the lithotomy 
position, 1.5 mL Permacol® was injected via a proctoscope into the sub-mucosa to produce a 
bulge just above the dentate line in each of the four quadrants[66, 68, 69]. The needle was 
retained in the injection tract for about 5 seconds to prevent the leakage of the bulking agent 
(Figure 6).  The procedure was repeated after three months in case of weekly FI episodes and 
in the absence of adverse events. For women allocated to Permacol®, the tined lead was left 
in place until 6 months’ follow-up. Crossover with delayed implantation of the IPG was 
offered in the case of an inadequate response to Permacol® at six months follow-up. 
 
Figure 6 Submucosal injection of bulking with collagen (Permacol®) via proctoscope. IAS= internal 





Permacol® was selected as bulking agent in this trial because the efficacy of an alternative 
compound (dextranomer in stabilized hyaluronic acid, NASHA Dx) was disappointing with 
no differences compared to traditional biofeedback [66]. Symptom scores and the QoL were 
also unchanged in a multicentre RCT comparing NASHA Dx with placebo [68]. On the other 
hand, Permacol® was believed to be incorporated into the tissue, resist breakdown by 






Baseline evaluations included civil and work status, body mass index (BMI), medical and 
obstetric history. Anorectal examination and EAUS was performed in all the women.  Patients 
were also asked to complete a two-week bowel habit diary and the questionnaires[41, 42, 79, 
89] used for outcome assessment. Although commonly applied as outcome measures for PNE, 
scoring systems such as the St. Mark’s score[41] and Rockwood QoL[42] are not designed or 
validated for measuring changes over a short intervals such as the three-week PNE period. 
Consequently, evaluation of PNE was based strictly on change of weekly FI episodes assessed 
with bowel habit diaries [50, 84].  
 
Outcome assessments of St Mark’s score, ICIQ-UI-SF and sexual function were performed 
blinded by telephone interview prior to the prescheduled follow-ups at baseline, 3 months, 6 
months and 12 months follow up.. The two-week bowel diary and QoL questionnaires were 
mailed for self-reporting. Self-reported outcome assessment (satisfied/not satisfied) was 
evaluated at 6 months follow up. Adverse events such as infection, pain or adverse changes in 
bowel or urinary function, were recorded during the follow-up consultation, not by telephone, 
because this could have revealed the treatment arm. An overview of the evaluation at different 













3,6 and 12 months follow-up  
Demographic data:  
Age (years) 
Menopausal status  
Body mass index (BMI, kg/m2) 
Obstetric history 
Previous surgical procedures 
3D EAUS defect score [46] 
  
Questionnaires 
St. Mark’s incontinence score [41]  
FI QoL score (Rockwood FIQL)[42]  
EQ-5D™ (EuroQol Group, Rotterdam, 
the Netherlands) 
UI (ICIQ-UI SF) [89] 
Sexual function [79] 
 Questionnaires 
St. Mark’s incontinence score  
FIQL score  
EQ-5D™  
ICIQ-UI SF 
Sexual function  
6 months: Patients satisfaction 
2-week bowel habit diary: 
Weekly FI episodes  
Weekly urgency episodes 
Weekly bowel-emptying episodes 
3-week bowel habit diary: 
Change in weekly FI 
episodes, urgency episodes, 
bowel-emptying episodes 
2-week bowel habit diary: 
Change in weekly FI episodes, 
urgency episodes, bowel-emptying 
episodes 
Procedure Sensory threshold  
Foramen (level) 
Adverse event  
Sensory threshold  
Adverse event  
 




The sphincter complex was examined with 3D EAUS with the patient in the lithotomy 
position at the time of inclusion. A Falcon ultrasound scanner was used (BK medical, 
Gentofte, Denmark). The 3D film of the anal sphincter complex was recorded from the distal 
part of the PRM to the anal opening by continuous motorized withdrawal. The 3D EAUS 
dataset was stored on a personal computer. The extent of the defect was classified according 
to the validated EAUS defect score [45, 46]. Classification was performed using the BK 3D 
viewer by an independent investigator (SN) blinded to clinical data. 
 
The EAUS defect score ranges from 0 (no defect) to seven (maximal defect with defect in 
both external and internal anal sphincter) (Table 5). Partial defects of IAS were excluded. 
Defects being complete at one level and partial at another level were defined as complete in 






Defect characteristics Score 0 Score 1 Score 2 Score 3 
 
External anal sphincter  
Length of the defect ≤50% >50%   





Internal anal sphincter 
Length of the defect ≤50% >50%   






Table 5 The EAUS defect score. The score is continuous and ranges from 0 to 7. The EAUS defect 
score is calculated by summarizing the value given from the different parameters, from external 
(maximum 4) and inter anal sphincter defect (maximum 3) [46]. 
 
 
Different classification systems are used to describe the extent of the sphincter defects. Both 
the EAUS defect score and the Starck score have been shown to correlate with the degree of 
FI following OASIS [90-92]. The EAUS defect score is the preferred classification system in 
our practice, because it has a continuous scale and do not classify partial defects of the IAS in 
contrast to the Starck’s score [46, 92].  
 
St	Mark’s	score	
St Mark’s incontinence score is an interview scoring system used to grade the severity of FI 
during the last four weeks. St Mark’s score consist of seven question and range from 0 (no FI) 
to 24 (maximal FI)[41]. Difference in the reduction of St Mark’s score from baseline to six 
months was the primary outcome measure in paper II. 
 
Bowel	habit	diary	
Patients completed a two -week bowel habit diary at baseline recording weekly FI episodes, 
differencing between urgency and passive FI episodes. Urgency was defined as inability to 
defer defecation for 15 minutes. In paper I, the bowel habit diary was used to assess primary 
outcome expressed as per cent reduction in weekly FI episodes, with a successful PNE 
defined as a 50% or greater reduction of weekly FI episodes. 
 
Faecal	incontinence	quality	of	life	scale		
The rockwood FIQL scale is a disease specific health related QoL questionnaire that has been 
translated and validated into Norwegian[42, 43]. FIQL is composed of 29 items based on self-
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report, rating from 0 (worst) to 4 (best). The items are dived into four subscales, which are the 
mean of all the items included in the respective scale: Lifestyle (10 items), Coping (9 items), 
depression (7 items) and embarrassment (3 items).  
 
EQ-5D-	3L	
The Euroqual 5- dimension 3-level (EQ-5D™-3L) is a commonly used generic QoL 
questionnaire that consists of five question assessing mobility, self-care, daily activities, pain 
and depression with 3 possible answers. The sum of the answers can be converted into the 
EQ-5D index that ranges from -0.543 (worst) to 1.0 (best).  A score less than 0 indicate QoL 
worse than death. In addition, a visual analogue scale (VAS) from 0 (worst) to 100 (best) is 
used to describe the patients’ self-perceived general health status. Normative data for the 
Norwegian population are not available [93, 94].  
 
ICIQ-UI-SF	
All women were screened for concomitant UI with the validated International Consultation on 
Incontinence Questionnaire for UI, Short Form (ICIQ-UI-SF)[89]. The ICIQ-UI-SF is 
constructed to measure both level of symptoms of UI and impact on lifestyle the last four 
weeks, and consist of three numeric questions and seven self-diagnostic items defining stress 
and urge UI. The ICIQ-UI SF ranges from 0 (no UI) to 21 (worst UI) and is graded from mild 
(1-5), moderate (6-12), severe (13-18) to very severe (19-21). UI was defined as concomitant 
if ICIQ-UI-SF score was one or greater[89].  Change in ICIQ-UI-SF from baseline to 12 
months was the primary outcome in the paper III. 
 
Sexual	function	
Sexual function was assessed by a translated non-validated questionnaire designed for women 
with OASIS, developed by an expert group [79]. The questionnaire is easy to use, can be 
applied for telephone interview and contains the following four questions: 1. Are you sexually 
active? (Yes/no) If no, state reason. 2. Is sex painful? (Yes/no) 3. Do you have any problems 
with sex? (Yes/no) If yes, state problem. 4. Are any of your sexual problems bothersome? 
(Yes/no). The expert group highlights the importance of assessment of bothersome sexual 






The purpose of paper I was to assess efficacy during PNE and relate the outcomes to baseline 
factors with special emphasis on the extent of sphincter defect in women with FI following 
OASIS. The primary outcome was efficacy defined as the per cent reduction in weekly FI 
episodes during PNE compared with baseline and the success rate of the PNE, with a 
successful PNE defined as a 50% or greater reduction in FI episodes.  
 
Paper	II	
The purpose of paper II was to compare the effectiveness of SNM with Permacol® in women 
with FI following OASIS. The primary outcome was the difference in the St. Mark’s score 
between baseline and 6 months. Secondary outcomes were changes in weekly FI episodes, 
disease-specific QoL (FIQL), generic QoL (EQ-5D), UI (ICIQ-UI-SF) and sexual function.  
 
Paper	III	
The purpose of paper III was to investigate the efficacy of SNM in women with a history of 
OASIS and combined UI and FI. The primary outcome was the change in ICIQ-UI-SF at 12 
months compared with baseline. Secondary outcomes included reduction of St Mark’s score, 




The sample size calculation was based on the power calculation from the RCT. The 
assumption was that a difference greater than 4 points in the reduction of the St. Mark’s score 
between baseline and 6 months between the SNM-group and Permacol® -group, was 
clinically relevant. Detecting this difference with a statistical power of 0.80 and a significance 
level of 0.05 with a two-sided test, and assuming a standard deviation of 5.0, would require 25 
patients in each group. Accounting for a dropout rate of 10%, assignment of 28 participants in 
each group was considered adequate. With a success-rate of PNE of 70-90 %, a total of 62-73 
women had to be enrolled and assigned to PNE. The sample size was calculated for the RCT 





In paper II, the participants were randomly assigned to receive either SNM or Permacol® 
with an equal allocation ratio (1:1), with randomly permuted block sizes of varying length (6 
and 4) to conceal the allocation. Patients were stratified according to the centre of recruitment.	
Allocation was performed by a computer-generated, real-time, web-based randomization 
system (www.ntnu.no/dmf/akf/randomisering) that generated random allocation sequences 
known only by the administrators responsible for developing the randomization system until 




Double blinding may be challenging in surgical trials. Because two different treatments were 
compared in this RCT, sham was not an option and blinding of patients and surgeons were not 
accomplished. To avoid assessment bias, the telephone interview prior to the 3- and 6-month 
follow-up was performed by a trained nurse (GN) who was blinded to treatment allocation 
throughout the study period. The patients were instructed not to reveal the treatment arm by 
an information letter mailed prior to the phone call. The classification of the extent of the 




Continuous variables were presented as mean with standard deviation (SD) or medians with 
interquartile range (IQR). Within group differences were analysed with paired t-test. Between 
group differences were analysed by independent t-test and linear regression models. The 
effect sizes were presented as the mean with 95% confidence interval (CI) and a two-sided 
significance level of 0.05. Model assumptions were assessed by residual analyses. For the 
linear regression analyses model assumptions were assessed by graphical inspection of the 
residual. The residuals should be approximately normally distributed and the the variance of 
the residuals should not depend on values of the independent variables (homoscedasticity). 
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The nonparametric Mann Whitney-U test and Wilcoxon signed rank test were used when 
assumptions not were met. Categorical data were reported as frequencies and percentages and 
compared using the chi-squared test or the two-tailed Fisher’s exact test. Correlations were 
assessed with Pearson correlation coefficients (r). Association and odds ratio (OR) were 
assessed with linear and logistic regression models, both unadjusted and adjusted.  A two-
sided P value <0.05 was considered statistically significant. All analyses were performed 
using the SPSS program, version 21.0-23.0 (SPSS Inc., Chicago, Illinois, USA).  
 
Linear and logistic regression models were used to assess the associations between efficacy 
during PNE (paper I) or effectiveness (paper III) and baseline independent variables with 
special emphasis on the extent of sphincter defect. Significant variables from unadjusted 
regression models were included in multivariable regression models. Outcome variables in 
paper II were analysed using a linear regression, unadjusted and adjusted for the baseline 
symptom scores as covariates (ANCOVA) according to recommendations [95, 96]. 
ANCOVA was pre-specified as the primary analysis in the study protocol. Binary variables 
were presented as the number and percentage, and analysis of group differences regarding 
change from baseline to 6 months was assessed by a generalized estimating equation using the 




We recognized that the study design in the RCT where a successful PNE was an inclusion 
criterion might have introduced a selection bias in favour of SNM, selecting patients 
responsive to SNM. To overcome this inherent selection bias, as recommended[50], a worst-
case scenario for SNM was created as follows: Of the seven women with unsuccessful PNE 
who were excluded, four were allocated to the Permacol® group. Each patient was given the 
best reduction in St Mark’s score obtained after Permacol® injections in the Permacol® 
group.  The other three were allocated to the SNM group, each given a reduction of zero in St 
Mark’s score (poorest possible). In this way, the best possible outcome after Permacol® 
injection could be compared with the worst possible outcome after SNM. The primary 
outcome was then analysed.  
 
Because of imbalanced recruitment between the two centres, an additional sensitivity analysis 





The CONSORT guidelines [97] were followed to ensure high quality of reported results and 
avoid bias in the RCT [98].  The consort guidelines facilitate standardized and transparent 
reporting and interpretation and consist of a statement, checklist and flow diagram. 
The CONSORT Statement is evidence-based recommendations for reporting randomized 
trials and comprises a 25-item checklist focusing on the design, analysis and interpretation of 





The prospective collection of data with the randomized design represents the highest level of 
evidence in evidence-based medicine.[4] Random allocation decreases selection bias and 
minimizes confounding variables when comparing the groups. Consequently, the conclusions 
are not due to chance if an adequate sample size has been calculated. 
 
One of the main strengths of the study was restricting the study group to women with FI 
following OASIS. This group represents the largest subgroup women with FI and treatment is 
based on low level of evidence[12]. Consecutive women were included irrespective of the 
size of the sphincter defect, which were classified blinded according to a validated 3D EAUS 
defect score. Another strength was a multidisciplinary approach with the use of validated 
questionnaires for blinded assessment of FI, UI and QoL. A non-validated questionnaire for 
sexual function was used, because it included assessment of bothersome sexual complaints. 
The advantages of questionnaires are that they are easy to apply, cost effective and they allow 
for masked outcome assessments.  
 
Finally, the standardization of the method including the tined lead and use of the new EPG 
was a strength. One advantage using a tined lead and not a temporary lead during PNE is the 
standardized positioning of the tined lead to achieve low motor and sensory thresholds on 
three to four poles. The stimulation during PNE becomes similar to permanent treatment. 
When achieved, low threshold stimulation is believed to improve the outcomes of both PNE 
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and permanent SNM[99-101]. The new EPG (Verify®)	is also more stable than the previous 
model and enables delivery of more accurate amplitude similar to permanent stimulation. 
 
Methodological	limitations	
Preferably, an RCT should be double blinded to prevent bias and protect the randomization 
sequence after allocation. Lack of blinding of participants may introduce a bias and the 
outcome estimates may deviate from the true effect of the intervention, either as an 
underestimation or an overestimation. It is possible, that participants in the Permacol® group 
would be disappointed by the allocation to a less expensive treatment, with less expectations 
and motivation to report improvement compared to participants in the SNM group who might 
have reported an exaggerated effect. Another possibility is that patients receiving the less 
effective treatment would search alternative treatment. Unmasked surgeons may also have 
transferred their attitudes about the different treatment to the participants, both unintentionally 
and intentionally. This could have impacted the outcome estimates. The lack of patient 
blinding is consequently a limitation of the trial.  
 
Questionnaires have limitations: The significance is primarily dependent on the reliability and 
the validity of the questionnaires. Secondly, questionnaires do not necessarily address the 
problems important for patients. Patients and health professionals may also have different 
view on the weighted severity of different symptoms [11, 29, 102]. The burden of FI and 
concomitant pelvic floor dysfunction may not be easily interpreted from the bowel habit 
diary, St Mark’s score and other questionnaires. Likewise, the efficacy of treatment is not 
automatically reflected by the changes in scores.  Interestingly, for EQ-5D-3L the normative 
data for the Norwegian population are not available. It is challenging to judge whether a 
difference is clinically relevant or not, making the interpretation uncertain. The lack of an 
international consensus in the definition, assessment and outcome-reporting for the treatment 
of pelvic floor dysfunction, is consequently one of the main limitations in these studies [11]. 
 
One disadvantage by many RCTs is the time used to perform a trial. While this trial was 
ongoing, clinical practice moved on. In light of current evidence, bulking agents as 
comparator to SNM may have been replaced by other treatments, like transanal irrigation, the 




The study protocol that formed the basis for application for funding and admission to the PhD 
program was completed in 2011. The study was funded by the medical research programme 
of the Health Authorities of North Norway, grant reference number ID 6916/SFP1049-12, 
with 50% salaries for 6 years, from 2012-2017. No commercial organizations were involved 
in the trial. MR has received honorarium from Medtronic for a presentation in September 
2016. The other authors have no disclosures.  
 
The study was initiated in February 2012 after The Regional Committees for Medical and 
Health Research Ethics, North Norway approved the protocol (number 2011/1300/REKnord). 
The trial was registered at ClinicalTrials.gov with number NCT01528995.  
 
Written informed consent was obtained from all participants at baseline. The consent included 
completion of the PNE period, treatment with Permacol® if unsuccessful PNE and 
randomized allocation to either Permacol® or SNM if successful PNE. The 50 % chance of 
allocation to the Permacol® group despite a successful PNE was thoroughly discussed with 
the patients before obtaining written informed consent. In addition, the consent contained 
















Between February 2012 and March 2014, 77 consecutive women were assessed for eligibility.  
A total of 63 women underwent the 3 weeks PNE period at UNN and 2 women underwent a 
PNE period at St Olav hospital. At UNN, one woman declined to participate, three were 
excluded according to exclusion criteria and another eight women signed, but withdrew 
informed consent for various reasons. The efficacy during PNE and relation to baseline 
factors is discussed in paper I.  
 
Of the 58 women with a successful PNE, 56 from UNN and two from St Olav’s Hospital were 
randomly assigned to SNM (n=30) or injection of Permacol® (n=28). Two patients withdrew 
their consent before	entering	treatment	in the Permacol®-group.	Except	for	these	two,	all	
patients	were available for analysis at six months. The comparison between the two treatment 
groups is presented in paper II.  
 
Crossover from one treatment arm to the other arm was allowed after 6 months. None of the 
patients in the SNM group crossed over to Permacol® compared to 18 of 26 (69%) who 
received Permacol® that crossed-over to SNM. Three of these women were lost to follow up: 
One patient discontinued treatment with SNM because of infection. Another reported 
intolerable pain possibly related to a chronic infection, not verified by culture. The third 
woman died of cardiac arrest, unrelated to SNM. Consequently, a total of 45 women were 
available for analysis 12 months after SNM. Paper III includes the analysis of the 37 women 
who reported combined FI and UI (DI). 
 
Another three patients (12%) in the Permacol® group preferred additional treatment other 
than SNM: A secondary sphincter repair was performed in one woman with a major defect of 
both EAS and IAS and with an EAUS defect score of 7. One chose transanal irrigation in 
combination with fibre supplements and another woman received a permanent colostomy. 
Finally, five women (19%) were satisfied with the result after Permacol® injection and did 





Figure 7 Flow chart of all the women with faecal incontinence following OASIS assessed for 
































































• 26 received Permacol® 












































The trial was closed in September 2015 after reaching the sample size and completing 12-
month follow-up examinations. In the same period, from February 2012 to March 2014, 14 
men and 15 women with FI without a history of OASIS underwent PNE at UNN. Secondary 
sphincter repairs and perineal reconstruction were performed in four women because of the 
combination of cloaca, large rectoceles or lack of perineal body. 
 
Baseline	characteristics	of	all	the	participants	(n=65)	
The mean age of the enrolled women were 56.5 (SD 12.5) years and 45 (69%) were 
postmenopausal. The mean BMI was 26 (SD 4.4). Forty-three (66%) lived with a partner. 




The women reported 2.0 (IQR 2.0-3.0) vaginal deliveries. In addition, 7 (11%) women had 
undergone one caesarean section and 5 (8%) two caesarean sections. A third degree OASIS 
was reported by 27 women (42%) and a fourth degree OASIS by 38 (58%) women. 
Instrumental assisted deliveries were reported by 17 (26%). A median of 39 (IQR 25.5-44) 
years had passed since the OASIS.  
 
The EAUS defect score was unavailable in 4 (6%) patients: In two patients the distal 
sphincter was not included in the EAUS data file and was thus impossible to score. The files 
were missing in the two patients from St Olav’s Hospital. An isolated EAS defect was 
identified in 46 (75%) patients and a combined EAS and IAS defect in 12 (20%) women, and 
the mean EAUS defect score was 2.7 (SD 1.8), median 2.0 (1.0-4.0). Two (3%) women had 
no structural defects after primary repair and one (2.%) woman following secondary repair. 
Eight (12%) women had been treated with a secondary sphincter repair between 3 and 17 
years prior to enrolment. 
 
Faecal	incontinence	
A total of 54 (83%) women reported FI for more than 5 years. Mean St Mark’s score was 17.3 
(SD 3.2). FI with urgency was reported by 49 women (75 %), passive FI was described by 
three (5 %) women and mixed FI by 13 (21 %). The median number of weekly FI episodes 
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was 4.5 (IQR 2.0-10), bowel-emptying episodes was 15.5 (IQR 10-23) and urgency episodes 
was 6.5 (IQR 4.0-12.5).  
 
Quality	of	life	
The generic QoL was measured using EQ-5D. The mean EQ-5D VAS score was 63.2 (SD 
20.8) and the EQ-5D index was 0.72 (SD 0.19). The four domains (lifestyle, coping, 
depression and embarrassment) of the disease specific Rockwood FIQL scale reflected the 




Concomitant UI defined as ICIQ-UI-SF score higher than zero was present in 47 women (72 
%). Figure 8 shows the distribution depending on severity of UI in all of the women. The 
overall ICIQ-UI SF score was 8.7 (SD 6.8) and 11.6 (SD 5.2) in the 47 women reporting UI. 
Urge UI was reported by 36/47 (77%). A total of 25/65 (38%) women had undergone 
previous surgery for UI, including 17 TVT (trans vaginal tape) operations. In five women UI 





Figure 8 The severity of urinary incontinence (UI) at the time of inclusion in all of the 65 women. A 















Nearly half  (n=31,48%) of the patients were sexually active. Of the sexually active women, 9 
(29%) reported pain and 23 (74%) reported other problems related to sexual activity, 
primarily fear of FI (n=20, 65%) during intercourse. Other concerns were general depression, 
vaginal dryness and appearance of external genitalia.  Nineteen (61%) of the sexually active 




A total of 63 women underwent a 3-week PNE period at UNN from February 2012-February 
2014 (Figure 9). 
 
Faecal	incontinence	
Fifty-six (89%) of the 63 women were responders with a successful PNE. Responders 
achieved a 94.5% reduction in weekly FI episodes, from median (IQR) 4.8 (2.0-11.0) to 0.5 
(0-2.0, p<0.001). Twenty-nine women (45 %) reported no FI episodes during PNE. The 
reduction in weekly urgency episodes was 82%, from 6.5 (4.0-12.5) to 1.0 (0-3.0, p<0.001). 
Urgency disappeared in 18 of the 56 (32%) responders. 
 
Relation	between	baseline	factors	and	outcome	
There were some differences in baseline characteristics between the responders and non-
responders, which are presented in (Table 7, appendix). Responders were more likely to be 
postmenopausal (p=0.03), with higher BMI (p=0.007), higher baseline St Mark’s score (p= 
0.004) and concomitant UI (p=0.034). The extent of the sphincter defect did not differ 




































































• 26 received Permacol® 













































In the multivariable logistic regression model, baseline St. Mark’s score was the only variable 
significantly associated with successful PNE, with an odds ratio of 1.47 (95% CI 1.01-2.14, 
p=0.046) (Table 8). Concomitant urge UI (p= 0.004) and BMI (p=0.03) were the two baseline 
factors significantly associated with per cent of reduction in weekly FI episodes in the 
multivariable linear regression model (Table 9). 
 
 
 Univariable regression model 
(Crude) 
 
Multivariable regression model 
 (adjusted*) 
 OR 95% CI P-value OR 95% CI P-value 
Menopausal status  6.83 1.20-39.1 0.031 3.32 0.37-30.1 0.29 
Body mass index 
(kg/m2) 
1.37 1.03-1.81 0.029 1.48 0.91-2.43 0.12 
St. Mark’s score (0-
24) 
1.51  1.11-2.05 0.009 1.47 1.01-2.14 0.046 
Urge UI 10.0 1.13-88.9 0.039 4.62 0.38-55.7 0.23 
 
Table 8 Odds ratios of successful PNE defined as 50% or more reduction in weekly faecal 
incontinence episodes using logistic regression models.*Mutually adjusted for variables significant 
from univariable model. OR=Odds ratio, CI= Confidence interval 
	
Adverse	events	
Pain during PNE was inversely related to efficacy (reduction in FI episodes during PNE) (R=-
0.29, p=0.02) and also related to unfavourable outcome in the adjusted linear regression 
model (p=0.046). Pain was also related to low BMI as eight of 22 (36%) with a BMI of less 
than 25 reported pain compared with 6 of 41 (15%) with a BMI>25 (R=0.25, p=0.049).  
 
 
 Univariable regression model 
(Crude) 
Multivariable regression model 
 (adjusted*) 
 Beta 95% CI P-value Beta 95% CI P-value 
Urge UI 26.5 12.9-40.2 <0.001 20.0 6.6- 33.5 0.004 
Body mass index 
(kg/m2) 
2.1 0.6-3.6 0.007 1.5 0.1-2.9 0.03 
FIQL Coping (0-4) -14.3 -27.5 to -1.1 0.03 -3.8 -17.6-10.0 0.6 
Eq-5D VAS (0-
100) 
-0.4 -0.7- 0.001 0.051 -0.2 -0.6-0.2 0.3 
Pain -20.9 -38.2- 3.5 0.02 -15.6 -31.5-0.4 0.046 
 
Table 9 Linear regression coefficients for the association between efficacy defined as percent 
reduction in weekly faecal incontinence episodes as dependent variable and urge urinary 
incontinence, Body Mass Index (kg/m2), QoL and pain. *Mutually adjusted for the listed variables. 
Beta=Linear regression coefficients, CI=Confidence interval 
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Paper	II		RCT	SNM	versus	Permacol®		
A total of 58 women were randomly assigned to receive SNM (n=30) and injection of 
Permacol® (n=28). All were available for analysis at six months except	for	the	two	patients	
who	withdrew consent before	receiving	Permacol® (Figure 10). Primary and secondary 
outcomes are available in Table 10 (appendix). 
   
 
































































• 26 received Permacol® 













































The reduction in the St. Mark’s score between baseline and 6 months was 11.2 (SD 5.3) in the 
SNM group versus 2.3 (SD 5.0) in the Permacol® group, resulting in a treatment difference of 





Figure 11 The reduction of St Mark’s score from baseline to six months in the SNM group compared 
to the Permacol® group. Illustration by Rod Wolstenholme.  
 
 
 A 50% or greater reduction in weekly FI episodes was accomplished in 28 (93%) women 
after SNM compared to nine (32%) following Permacol® application (p=0.001). Complete 
continence without weekly FI episodes, was described by 17 (57%) after SNM compared to 
three patients (11%) after Permacol® (p<0.001). Weekly urgency episodes disappeared in 




SNM was superior to Permacol® regarding the four domains of the FIQL, including lifestyle 
(0.90, 95% CI 0.50-1.30, p<0.001), coping (1.05, 95% CI 0.62-1.47, p<0.001), depression 
(0.52, 95% CI 0.16-0.87, p=0.005) and embarrassment (0.95, 95% CI 0.50-1.40, p<0.001). 
Women with SNM achieved an improvement in their EQ-5D™	global	health	score	(0-100)	
of	11.1 (SD 21.9) compared to 2.7 (SD17.8) in women treated with Permacol®, but the 
difference (8.4, 95% CI -2.4-19.3) was not significant (p=0.12). The difference in the EQ-5D 
index (0.031, 95% CI -0.14-0.07; p=0.55) was likewise not significant. 
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Overall, 23 (77%) women in the SNM group were satisfied with their treatment after 6 
months compared to only 3 (11%) satisfied women in the Permacol® group (p<0.001).  
 
Urinary	incontinence	
Concomitant UI was reported by 27 (90%) in the SNM group and 16 (61%) in the 
Permacol®-group. The mean reduction in the ICIQ-UI-SF score in the SNM– group was of 
5.3 (SD 5.8) compared 0.27 (SD 5.4) in the Permacol®-group, giving a difference in score of 
5.0 (95% CI 1.97-8.02 p=0.002) in favour of SNM; when adjusting for the baseline ICIQ-UI-
SF score, the difference was 3.0 (0.2-5.9, p=0.037). 
 
Sexual	function	
There was some imbalance in baseline sexual activity, as there were 19 (63%) sexually active 
women in the SNM group and 8 sexually active women (29%) in the Permacol® group. There 
was no significant difference after 6 months in the number of sexually active women (16 in 
the SNM group versus 6 in the Permacol® group; p=0.80). Overall at baseline, 14/19 (74%) 
in the SNM group had a sexual complaint compared to 7/8 (88%) in the Permacol® group. 
After six months, 5/16 (31%) in the SNM group had a sexual complaint compared to 5/6 
(83%) in the Permacol® group (p=0.26). The number of women reporting bothersome sexual 
problems from baseline to 6 months changed from 11/19 (58%) to 4/16 (25%) in the SNM 
group compared with a change from 6/8 (75%) to 5/6 (83%) in the Permacol® group 
(p=0.061, in between group difference). 
 
Adverse	events	
There were 9 (35%) minor adverse events in the SNM group compared to seven (27%) in the 
Permacol® group (p=0.77). No infections were detected in either of the groups. After SNM, 
one patient reported pain related to the IPG and one described painful stimulation in the 
extremities. Five women reported a deterioration of urinary function, which resolved after 
resetting of the IPG. Two women were referred to specialists for further investigation after 6 
months because of deterioration of UI. The IPG was reset during follow-up in 17 (57%) 
patients, including an adjustment of the amplitude from 1.05 (SD 0.48) mA to 1.41 (SD 0.85) 
mA and readjustment because of pain (n=1) or deterioration of urinary function (n=7).  
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Two (8%) women did not receive a second injection with Permacol® because of anal pain 
after the first injection, and another woman refused because of lack of effectiveness. Five 
(19%) reported mild symptoms of obstructed defecation that did not require treatment. 
 
Additional	analysis	
In the best-case scenario for Permacol®, the four allocated to the Permacol® group were 
given a reduction of St Mark’s score of 16. This resulted in an estimated reduction of St 
Mark’s score of 4.1 (95% CI 1.7- 6.6) in the Permacol®-group compared to an estimated 
reduction of St Mark’s score of 10.1 (95% CI 7.9-12.3) in the worst case scenario in the 
SNM-group. The difference of 6.0 (95% CI 2.7-9.3) did not affect the highly significant 
effectiveness of SNM compared with Permacol® (p=0.001).  The sensitivity analysis, 
excluding the two patients from St Olav’s Hospital because of imbalanced recruitment 
between the two centres, did not affect the outcome with a difference in the effectiveness of 




A total of 48 women received SNM, of whom 30 were randomly assigned to SNM and 18 
crossed over after primary allocation to injection of Permacol® after successful PNE. Three 
were lost to follow-up as described in the study overview. The eight women with isolated FI 
were excluded, providing 37 women with DI available for analysis 12 months after SNM 




Figure 12 Flow chart illustrating the assignment of the 37 women with double incontinence following 


































































• 26 received Permacol® 














































The overall reduction in ICIQ-UI-SF score from baseline to 12 months was 5.8 (95% CI 3.7-
8.0), from 12.4 (SD 5.1) to 6.5 (SD 5.8) (p<0.001) (Table 9). The change in ICIQ-UI-SF 









Figure 13 Change in ICIQ-UI-SF score from baseline to 12 months after SNM for each of the 37 
women with combined faecal and urinary incontinence (double incontinence). ICIQ-UI SF= 
International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form. It 
























A significant shift in the severity of UI was also observed, with 16 (43%) women reporting 
severe UI at the time of inclusion compared to 4 (11%) 12 months after SNM (p<0.001). 
Another 13 (35%) women reported no UI after 12 months (p<0.001) (Figure 14). Urgency 




Figure 14 The shift in severity of urinary incontinence (UI) from the time of inclusion compared to 12 
months after SNM in the 37 women with double incontinence following OASIS. Note that all reported 
concomitant UI at baseline compared to 13 (35%) with no UI after 12 months. 
 
Faecal	incontinence	
The mean reduction in the St Mark’s score from baseline to 12 months was 10.6 (95% CI 8.6-
12.7, p<0.001), from 17.8 (SD 2.6) to 7.1 (SD 5.3) (Table 11, appendix). Faecal urgency was 
reported by one (97%) compared with 13 (33%) at 12 months (p<0.001). Complete 
continence without weekly FI episodes, was reported by 23 (62%) (p<0.001). No 
improvement was reported by 3 (8%), giving a success-rate of more than 90% for FI in the 
patients with DI compared to 81 % for UI.  
 
Quality	of	life		
The mean EQ-5D VAS score changed from 59 (SD 20.4) at baseline to 73 (SD 17.8) at 12 
months, giving an overall improvement in general health of 15 (95% CI 5.6-24.9, p=0.003). 



















bothering component of the ICIQ-UI-SF score (0 best-10 worst) was reduced from 6.2 (SD 
3.3) at baseline to 3.3 (SD 3.4) after 12 months, giving a mean difference of 2.9 (95% CI 1.6-
4.2). All four domains of the Rockwood FIQL scale (0 worst, 4 best) changed significantly: 
lifestyle changed by 1.1 (95% CI 0.71-1.4), coping by 1.2 (95% CI 0.89-1.5), embarrassment 
by 1.3 (95% CI 0.89-1.6) and depression by 0.67 (95% CI 0.38-0.95) (Table 11, appendix). 
 
Sexual	function	
Of the 23 (59%) women who reported being sexually active at baseline, 17 (74%) were 
sexually active 12 months after SNM (p=0.25). Among sexually active women, sexual 
function improved. Pain during intercourse was reported by eight (35%) at baseline compared 
with four (17%) after 12 months (p=0.046). Fear of incontinence during intercourse was 
defined as a major problem by 17 (74%) at the time of inclusion, but only by 11 (46%) 12 
months after SNM (p=0.034). However, the change from 14 (61%) to 10 (59%) women 
stating that their sexual problems were bothersome was not significant (p=0.32).  
 
Logistic	regression	model	
The only baseline factor related to a successful outcome in terms of reduction of the ICIQ-UI-
SF score 12 months after SNM, was a higher baseline ICIQ-UI-SF score, with an OR per 







Of the 45 women who had SNM at 12 months follow-up, 3 were non-responders. Responders 
were more likely to report concomitant UI and low score on the embarrassment item of the 




In addition to the 26 women randomly assigned to Permacol®, the seven women with an 
unsuccessful PNE received Permacol®. Only five women randomly assigned to Permacol® 
and four women with unsuccessful PNE continued without additional treatment after 6 
months. The nine responders had higher baseline score of the embarrassment item of 
Rockwood FIQL scale . They were less likely to report concomitant UI as only 2/9 (22%) 
responders reported UI compared to 17/24 (71%) non-responders, with an OR of 8.5 (95%CI 
1.403-51.48, p=0.032). Table 12 shows the OR of response to Permacol® using a 





 Univariable regression model 
(Crude) 
 
Multivariable regression model 
 (adjusted*) 
 OR 95% CI P-value OR 95% CI P-value 
FIQL Embarrassment  8.99 1.53-52.7 0.015 5.62 0.96-32.7 0.056 
Urinary Incontinence 
score (ICIQ-UI-SF ) 
0.83 0.70-1.01 0.027 0.88 0.72-1.12 0.23 
 
Table 12.   Odds ratios of successful treatment with Permacol® (n=33) using logistic regression 








There were no significant difference in St Mark’s score at 12 months between the group who 
received SNM (n=30) and those who received the combination of Permacol® and SNM 





This is one of the largest prospective series in which efficacy during PNE, using a tined lead 
and the Verify® EPG, was related to baseline factors in women with FI following OASIS. 
The vast majority had successful outcomes; nine of ten were responders with a reduction in 
weekly FI episodes of more than 90%. The baseline St. Mark’s score was the sole factor 
predicting PNE outcome in the multivariable logistic regression model. In the multivariable 
linear regression model, concomitant UI and a higher BMI were related to greater reduction in 
weekly FI episodes. Pain during PNE was related to unfavourable outcome, whereas the 
extent of the sphincter defect did not affect the outcome[103].   
	
A 90 % reduction of FI episodes during PNE, are shown to be predictive of patient 
satisfaction with SNM [104] and with a lower probability of failure of SNM over the long 
term [63-65]. Our PNE success rate is higher than the 66.8% success rate from the European 
SNS outcome study group [63] but similar to the results of a recent review including 119 




St. Mark’s score was a positive predictor of successful PNE. Except for the importance of 
loose stool consistency [101], the severity of FI at baseline has not been related to PNE 
outcome [63, 64, 105, 106]. A greater improvement in postmenopausal women with more 
severe FI, may be explained by the fact that these women have more to gain than younger 
patients with a more recent repair, a better recovery capacity and less comorbidity. This idea 
is supported by a meta-analysis in which greater improvement after SNM was observed in 
postmenopausal women with severe FI [107]. Moreover, given that sphincter injury is only 
one factor in the complexity of FI [38], a higher St. Mark’s score may express more severe 
and complex damage to the pelvic floor. The finding that concomitant UI was correlated to a 
greater reduction in weekly FI episodes supports this. It is possible that SNM works better in 
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severe FI and concomitant UI because it has the potential to modify all aspects of the 
coordinated neuromuscular functions required for both urinary and bowel control [38, 62] , 
	
BMI	
A higher BMI was associated with a greater reduction in weekly FI episodes during PNE. The 
literature is inconsistent regarding an assumed association between BMI and efficacy during 
PNE both for FI and UI, but increased rates of reoperations and complications have been 
described in SNM patients with lower BMI or change in BMI [108-112]. While series 
exploring predictors of SNM for FI have failed to show an association between BMI and 
outcomes [64, 105, 106], a relation between low BMI and unfavourable outcome as shown in 
our study has also been demonstrated in urological patients [108, 109, 112] and children 
[110]. Bilateral migration of tined leads in a thin patient is thoroughly discussed by Kessler et 
al in 2005 [112]. A possible mechanism may be that the lead is more prone to displacement 
with subsequent reduced efficacy in thinner patients who have less lean muscle and 
subcutaneous tissue to anchor the tined lead [112]. Additional factors responsible for lead 
migration could be distension of pelvic organs and the stiffness of the tined lead [112]. 
Variations in the lead position may even generate painful stimulation. If pain necessitates a 
reduction in amplitude, the efficacy can be reduced [113]. Finally, leaner patients with less 
protective tissue might be more physically active during the PNE period and thereby more 
susceptible to lead breakage following minor trauma. This mechanism has been described in a 
paediatric population [110].   
 
Pain	
Previous reports [64, 114] have not elucidated the manner in which pain affects PNE 
outcomes although leg pain is a documented cause of the long-term failure of SNM despite 
attempts to resolve the problem by reprogramming [38, 65]. Pain during the PNE period is 
unpleasant for the patient, and reducing the amplitude to resolve the undesirable stimulation is 
likely to reduce efficacy [113]. If pain is recognized during lead placement although a low 






The extent of sphincter defect expressed with the EAUS defect score, was not related to 
outcome. The literature is conflicting regarding the importance of the extent of sphincter 
defect and PNE outcome. Some researchers observe no relation, whereas other studies have 
suggested that an EAS defect increases the risk of PNE failure without excluding patients 
from SNM. Caution should be exercised when drawing conclusions from our limited material 
because few women had large defects. Nevertheless, our results show that the presence of a 
sphincter defect does not preclude PNE.  
 
Paper	II	
This is the first RCT to compare the effectiveness of SNM and injectable bulking agents for 
FI following OASIS. SNM was superior to Permacol® at six months compared with baseline 
in terms of reducing the St Mark’s score and ICIQ-UI-SF score, changing of FIQL score and 
improving patient satisfaction [115]. 
 
Faecal	incontinence	
The primary outcome, the reduction of the St Mark’s score, clearly illustrated the difference 
in effectiveness between the two treatments in favour of SNM. The effectiveness of SNM was 
similar to findings from several published case series and some RCTs, with regard to reducing 
symptom scores, number of weekly FI episodes, achieving complete continence in more than 
a third of patients, improving the ability to defer defecation, all categories of FIQL score 
when assessed, and achieving effectiveness unrelated to the extent of the sphincter defect [38, 
50, 85]. The effectiveness of Permacol® was rather disappointing compared with three series 
of Permacol® showing success rates of 53%, 56% and 72% [67, 69, 70], but similar to a pilot 
trial comparing perianal injection of 15 ml Permacol® and Bulkamid® [116].  
 
St Mark’s score below 9 after treatment is assumed to be clinically significant and associated 
with improved QoL [87]. This outcome was achieved after SNM, but not after Permacol® 
application. The patients in the SNM-group achieved corresponding improvements of their 
FIQL scores compared to no improvement following Permacol®. The lack of clinical 
improvement of Permacol® was further demonstrated by the fact that only 11% of the women 
were satisfied with Permacol® after 6 months compared to approximately three-quarters of 




Three-quarters of the women reported concomitant UI compared to a previous reported 
prevalence of 30%- 50% [7, 80, 117]. The high prevalence of concomitant UI may be 
explained by the systematic assessment using a validated questionnaire with a low cut-off 
value defining UI. SNM was superior to Permacol® in the treatment of concomitant UI in 
terms of reduction of the ICIQ-UI-SF score. 
 
We did not expect Permacol® to improve concomitant UI as Permacol® acts locally in the 
anal canal and prevents FI by sealing the anal canal. In contrary, because SNM originally was 
developed for UI [118],  some improvement of concomitant UI was predictable [51, 62, 118]. 
The study was not powered to detect differences of improvement in subgroups, but SNM may 
be an appropriate treatment for women with DI [49, 80, 119, 120]. SNM for DI is further 
discussed in paper III. 
 
Sexual	function		
Two thirds of the patients were postmenopausal, half of the women were living along and the 
majority reported a severe symptom load of FI with major impact on QoL. In the SNM group, 
sexual complaints and bothersome sexual problems decreased, but the differences between the 
groups were not significant.  
 
Assessing female sexual function is challenging and changes after intervention are difficult to 
interpret. Many patients suffering from anxiety and depression avoid intimate relationships 
and choose to live alone, indicating the close relationship between sexual function, UI, FI and 
QoL [29, 121]. The RCT was not powered to detect differences of improvement in the 
subgroups, considering the imbalance between the groups regarding sexual activity. The 
statistical tests relate to only a small subgroup of the randomized patients, making the analysis 
and comparison between the groups rather difficult [115].  
 
Placebo	
The clinical relevance of bulking agents has been questioned in a recent Cochrane review 
[51]. A minority of the women who received Permacol® reported alleviation of symptoms. 
The supplementary analysis indicated that these women had a minor symptom-burden, with 
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no UI and with better QoL scores. At least three different RCTs have shown that one-third of 
the patients who received sham-treatment for FI was considered as responders [68, 122, 123]. 
The placebo effect should not be neglected [51]. It is challenging to determine whether the 
effectiveness of Permacol® observed in one-third of the patients represent the placebo-effect 
or a potential group highly selected patients who might benefit from treatment with 
Permacol® [124]. However, Permacol® has no place in the treatment algorithm for severe FI 
and concomitant pelvic floor dysfunction following OASIS despite its simplicity, minimal 




The women treated with SNM for FI after OASIS also experienced a reduction of UI when 
present. The improvement of concomitant UI in terms of reduction of the ICIQ-UI-SF score 
was observed in three quarters of the women. UI and urgency disappeared in one-third of the 
patients. Higher baseline ICIQ-UI-SF scores predicted successful outcome. More than 90% 
reported improved FI in terms of reduction of St Mark’s score. Sexually active women 
reported less pain and fear of incontinence during intercourse and increased QoL. 
 
Double	incontinence	
Concomitant UI improved in this group of mainly postmenopausal women with severe FI 
resistant to conservative treatment. The results were comparable for SNM for UI in general, 
with improved UI in two-thirds of patients after two years [125, 126]. A retrospective series 
including 57 patients with DI showed that UI improved in 78% of the patients and FI in 96% 
[119]. A discrepancy in success-rate for UI from 20 to 100% in a recent review on SNM for 
DI was explained by variation in patient selection and use of different outcome measures [80]. 
Success rates for FI are recognized to be superior to success rates for UI after SNM [38, 118].  
 
Some of the women reported deterioration of UI despite successful treatment of FI. 
Unfavourable changes in urinary function following SNM for FI have been described 
previously and can be restored by readjustments of the IPG [114]. Deterioration of UI may 
also reflect conditions requiring additional management other than SNM [80]. A third 
possibility is that successful treatment of FI changes the perception of the remaining 
symptoms of UI, resulting in a higher bother score. 
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A higher ICIQ-UI-SF score predicted successful outcome for the treatment for UI similar to 
the findings from paper I where concomitant UI was shown to be associated with successful 
outcome of PNE [103]. This may indicate that severe concomitant UI is a predictor of 
successful outcome after SNM.  
 
Sexual	function	
Among sexually active women, sexual function improved in term of less pain and fear of FI. 
However, the change in women stating that their sexual problems were bothersome was not 
significant. 
 
A recent published review on the impact of SNM on female sexual function reported 
improved sexual function in all included studies, but different outcome measures were used 
[127]. In the present study, a questionnaire developed by an expert group on OASIS was 
chosen [79]. The expert group highlighted the importance of assessment of bothersome sexual 
problems to avoid over-diagnosis of sexual complaints. This has to be considered when 
analysing outcome, and cautions is advocated when drawing conclusions on the effectiveness 
of SNM on sexual function [128].  
 
Quality	of	life	
Double incontinence is a more severe manifestation of pelvic floor dysfunction and is 
associated with a greater impact on QoL than the two conditions separate [129, 130]. DI 
causes psychological distress, and many women suffer from anxiety and depression [81, 102, 
129, 130]. This is consistent with our findings with low disease specific QoL scores at 
baseline. Generic and disease-specific QoL, including all four domains of the Rockwood 
FIQL scale and the bothering component of ICIQ-UI-SF score, improved 12 months after 
SNM. This is consistent with previous findings were bowel and urinary related QoL and 







Different clinical questions and aspects of treatment for FI and concomitant pelvic floor 
dysfunction in women with a history of OASIS have been investigated: 
 
Faecal	incontinence	
The vast majority of the women had successful outcome after PNE, and a higher St Mark’s 
score predicted successful outcome of PNE. Women who received SNM achieved St Mark’s 
score below 9, which is assumed to be clinically significant and associated with improved 
QoL. FI and urgency completely disappeared in more than one third after SNM compared to a 
rather disappointing effectiveness of Permacol®.  
 
SNM was superior to Permacol®, with three-quarters of the women were satisfied with SNM 
compared to only 10% after Permacol®. Considering the 30 % placebo effect in the treatment 
of FI [68], we conclude that Permacol® has no place in the treatment algorithm for substantial 
FI following OASIS.  
 
Sphincter	defect	
No association between the extent of the sphincter defect assessed with EAUS defect score 
and outcome during PNE, after SNM or after Permacol® was revealed. SNM should be 
considered as the first-line treatment for all women with FI following OASIS after failure of 
conservative management, regardless of the extent of sphincter defect, in the absence of other 
indications for perineal reconstruction [38, 64, 85, 106, 107, 131, 132].  
 
Quality	of	life	
The burden of severe FI and pelvic floor dysfunction causes psychological distress. Treatment 
of FI and concomitant pelvic floor dysfunction improves patients satisfaction, disease specific 






Three quarters of the women reported DI. UI was successfully treated with SNM in terms of 
reduction of ICIQ-UI-SF, complete continence and disappearance of UI in one third, 
compared to no change after Permacol®. Concomitant urge UI was related to successful 
outcome of PNE and higher baseline ICIQ-UI-SF scores predicted successful outcome after 
SNM.  
 
SNM seems to be a suitable treatment for the majority of the women with DI. Evaluating UI 
with a simple questionnaire like ICIQ-UI-SF can be valuable for colorectal surgeons when 




Only half of the women were sexually active, reflecting the complexity and burden of pelvic 
floor dysfunction. Sexually active women reported less pain and fear of incontinence during 
intercourse 12 months after SNM, but bothersome sexual problems did not change 
significantly. Assessment of bothersome problems has to be considered when analysing 
change in pelvic floor function, and caution is advocated when drawing conclusions on the 
















An international initiative is warranted to achieve consensus on how to define FI and 
concomitant pelvic floor dysfunction, assess severity and report outcome. It is essential to 
possess robust outcome measures considering the bothering and burden of the symptoms and 
impact on QoL. Patients and health professionals may have different view on the weighted 
severity of different symptoms. When evaluating new treatments, overestimation of the 
benefits and underestimation of adverse events can be misleading. New treatment for FI 
should be rigorously evaluated in well-designed multicentre trials allowing safe and 




The value of the PNE is under critical appraisal with the up-coming OneStage trial. A one-
stage implant simplifies the patient’s flow and management with one instead of two 
procedures requiring anaesthesia and an operating theatre. This could reduce the risk of 
implant infection, and patients could avoid restrictions related to an external system. A one-
stage procedure will most likely save resources for the health system, although improved 
outcome after one stage compared to two stage is not expected.  
 
 The trial incorporates the standardization of SNM to ensure optimal placement of the tined 
lead along the nerve. Introducing the curved stylet, which was not used in this study, is an 
essential step. This may contribute to additional benefits and improved outcomes for the 
patients. The trial is also designed to investigate for a potential placebo effect of SNM in the 





David Hume (1711- 1776) stated that medicine relies on facts and values. Values are not 
derived from facts or determined by the way the world is. Medicine depends on scientific 
facts, but health professionals need to value and choose between available options to 
accomplish high quality of diagnosis, tailored treatment strategies and care based on the 
individual’s symptoms and expectations [133].  This may be facilitated by organization of 






















“The genius of the mind is to create a model of the world which is both useful and that, until 






















































































































































































































































































































































































































































































































































 Frequency Mean(SD) Median (IQR) 
Demographics 
Age (years)  56.5 (12.5) 59 (47-67) 
Civilian status    
In a relationship 43 (66%)   
Alone 22 (34%)   
Body mass index (BMI, kg/m2)  26.0 (4.4) 25.2 (22.1-27.8) 
History of a systemic disorders 15 (23%)   
Hypothyreosis 3 (5%)   
Arthritis including psoriasis arthritis 4 (6%)   
Sjogren´s Syndrome 3 (5%)   
Diabetes Mellitus (yes) 5 (8%)   
History of a neurological disorder (yes) 10 (15%)   
Operation for back injury  5 (8%)   
Obstetric history 
Postmenopausal status 
premenopausal 20 (31%)   
postmenopausal 45 (69%)   
Vaginal deliveries  2.5 (1.1) 2 (2-3) 
Instrumentation yes 17 (26%)   
Degree of OASIS 
3th degree 27 (42%)   
4th degree 38 (58%)   
EAUS defect score (0-7)  2.7 (1.8) 2.0 (1.0-4.0) 
No defect 3 (5%)   
EAS defect 46 (71%)   
Combined EAS/ IAS defect 12 (18%)   
Missing 4  (6%)   
Faecal incontinence 
St Mark’s score (0-24)  17.3 (3.2) 18 (15-20) 
Type of FI 
Urge  47 (72%)   
Passive 3 (5%)   
Mixed 15 (23%)   
Bowel habit diary 
Weekly bowel emptying episodes  16.9 (8.8) 15.5 (10-23) 
Weekly FI episodes  7.5 (8.8) 4.5 (2-10) 
Weekly urgency episodes  8.9 (6.9) 6.5 (4-12.5) 
Duration of symptoms 
<1 years -   
1-5 years 11 (17%)   
6-10 years 26 (40%)   
>10 years 28 (43%)   
Previous secondary sphincter repair (yes) 8 (12%)   
Quality of life (QoL) 
EQ-5D  
EQ-5D VAS (0-100)  63.2 (20.8) 70 (50-80) 
EQ-5D index (-0.453-1)  0.72 (0.19) 0.78 (0.66-0.83) 
Rockwood faecal incontinence quality of life (FIQL, 0-4) 
Lifestyle  2.56 (0.81) 2.7 (2.0-3.2) 
Coping  1.71 (0.58) 1.63 (1.22-2.11) 
Depression  2.93 (0.92) 3.14 (2.14-3.71) 
 77 
Embarrassment  1.81 (0.62) 1.67 (1.33-2.0) 
Urinary incontinence (UI) 
ICIQ-UI-SF score (0-21)  8.7 (6.8) 8.0 (0-15.0) 
UI (yes) 47 (72%)   
Urge UI 27 (57%)   
Stress UI 11 (23%)   
Mixed UI 9 (19%)   
Operation for UI (yes) 25 (38%)   
Previous TVT (yes) 17  (26%)   
Cured after TVT 5 (29%)   
Sexual function 
 Sexual active (yes) 31 (48%)   
Pain (yes)* 9 (14%)   
Other problems (yes)* 23 (74%)   
Bothering problems (yes)* 19 (61%)   
 
Table 6  Demographic data and baseline characteristics of all the 65 included women (new). Values are 
expressed as either numbers (percent) or means (standard deviation, SD) and median (interquartile range, 
IQR).OASIS=obstetric anal sphincter injury. EAUS=endoanal ultrasonography. EQ-5D=European Quality of 
Life-5 Dimensions. ICIQ-UI SF= International Consultation on Incontinence Questionnaire- Urinary 

















































Age, years 61 (50-67) 43 (41-67) 0.2 
Menopausal status   0.03 
Premenopausal	 15 (27%) 5 (71%)  
Postmenopausal 	 41 (73%) 2 (29%)  
Body mass index, kg/m2 27 (24-31)  24 (22-25) 0.007 
Obstetric history    
Vaginal deliveries	 2.0 (2-3) 2.0 (1-2) 0.09 
Instrumentation	 16 (29%) 1 (14%) 0.7 
Degree of OASIS   0.4 
      3rd degree rupture	 21 (38 %) 4 (57%)  
      4th degree rupture	 35 (62%) 3 (43 %)  
EAUS defect score (0-7) 2.0 (1-4) 3.0 (1-4) 0.4 
Previous secondary sphincter repair 6 2 0.2 
Previous anorectal surgery 14 (25%) 3 (43%) 0.09 
Previous gynaecological surgery including 







St. Mark’s score (0-24) 18.0 (15.3-20.0) 15.0 (12-16) 0.004 
Duration of FI   0.4 
1-10 years 30 (54%) 5 (71%)  
More than 10 years 26 (46%) 2 (29%)  
Rockwood quality of life score     
Lifestyle (0-4)	 2.6 (1.9-3.2)  3.0 (2.1-3.6)  0.3 
Coping/behaviour (0-4)	 1.6 (1.2-2.1)  1.9 (1.6-2.4)  0.1 
Depression (0-4)	 3.0 (2.1-3.8)  3.2 (2.4-3.6) 0.6 
Embarrassment (0-4)	 1.7 (1.3-2.0)  2.3 (1.3-2.7)  0.3 
EQ-5D™    
General health (VAS scale 0-100) 63 (50-78) 90 (54-90) 0.1 
Urinary Incontinence 44 (79%) 3 (43%) 0.06 
Urge urinary Incontinence  36 (97%) 1 (14%) 0.04 
ICIQ-UI SF score (0-21) 8 (3.3-15.8) 0 (0-9) 0.07 
Table 7 Demographic data and baseline characteristics of responders (≥50% reduction in faecal incontinence 
episodes) compared with non-responders (<50% improvement in faecal incontinence episodes) during PNE 
(paper I). Values are expressed as either numbers (percent) or median (interquartile range). OASIS=obstetric 
anal sphincter injury. EAUS=endoanal ultrasonography. EQ-5D=European Quality of Life-5 Dimensions. 





























baseline to 6 
months 
 
Difference in change from baseline to 6 months 












St Mark’s incontinence score (0-24) 





Permacol®  16.8 (3.4) 14.3 (4.5) 2.3 (5.0) 
 
Faecal incontinence quality of life scale (FIQL) 
 
Lifestyle (0-4) 





Permacol®  2.63 (0.85) 2.83 (0.83) 0.15 (0.61) 
 
Coping (0-4) 
SNM  1.54 (0.48) 2.79(0.79)  1.25 (0.84), 1.05  
(0.62-1.47) 
<0.001 0.94  
(0.53-1.34) 
<0.001 
Permacol®  1.76 (0.59) 1.9 (0.73) 0.20 (0.72) 
 
Depression (0-4) 
SNM  2.86 (0.87) 3.51(0.69)  0.65 (0.66) 0.52  
(0.16-0.87) 
0.005 0.53  
(0.18-0.53) 
0.001 
 Permacol®  2.83 (0.95) 2.97 (0.94) 0.14 (0.64) 
 
Embarrassment (0-4) 
SNM  1.72 (0.64) 3.03(0.78)  1.28 (0.84) 0.95  
(0.50-1.40) 
<0.001 0.94  
(0.49-1.38) 
<0.001 




EQ-5D VAS scale (0-100) 





Permacol®  65.2 (20.9) 67.2 (22.8) 2.7 (17.8) 
 
EQ-5D index (-0.594 –1) 
SNM  0.68 (0.20) 0.74 (0.20) 0.059 (0.20) 0.031  
(-0.073-0.14) 
0.55 0.011  
(-0.074-0.095) 
0.80 
Permacol®  0.75 (0.18) 0.78 (0.14) 0.028 (0.19) 
 
Urinary incontinence 
ICIQ-UI SF score (0-21) 
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Table 10 Differences between the SNM group (n=30) and Permacol® group (n=26) regarding the changes in 
the primary and secondary outcomes from baseline to 6 months  
 
Values are mean (standard deviation). Difference in change (B) is reported as the mean (95% confidence 
interval) and was calculated with linear regression models, both unadjusted and *adjusted for baseline values.  
St Mark’s incontinence score ranged from 0 (continent) to 24 (complete incontinence). FIQL= faecal 
incontinence quality of life. Its score ranged from 0 (worst) to 4 (best). Eq-5D= Euroqual 5-dimension. Eq-5D™ 
VAS ranged from 0 (worst) to 100 (best), and the index ranged from -0.594 (worst) to 1 (best). ICIQ-UI SF= 
International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form. It ranged from 0 

















































SNM 11.3(6.45) 6.1 (6.12) 5.3 (5.8) 5.0x 
(1.97-8.02) 
0.002 3.04  
(0.19-5.89) 
0.037 





 Baseline 12 months Change (95% CI) p-value 
Urinary incontinence 
International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form 
(ICIQ-UI-SF) score 0 (best) to 21 (worst) 
Mean (SD) 12.4 (5.1) 6.5 (5.8) -5.8 (3.7-8.0) <0.0001 
Median (IQR) 13.0 (8.0-17.5) 8.0 (0-11.0) - <0.0001 
Faecal incontinence 
St Mark’s score 0 (best) to 24 (worst) 
Mean (SD) 17.8 (2.64) 7.1 (5.3) -10.6 (8.6-12.7) <0.0001 
Median (IQR) 18.0 (15.0-19.5) 6.0 (3.0-11.0) - <0.0001 
Quality of life 
EQ-5D Vas scale 0 (worst) to 100 (best) 
Mean (SD) 59 (20.4) 73 (17.8) 15.2 (5.6-24.9) 0.003 
Median (IQR) 60 (48-75) 75 (70-82) - 0.008 
EQ-5D index -0.594 (worst) to 1 (best) 
Mean (SD) 0.68 (0.20) 0.73 (0.21) 0.047(-0.04-0.13) 0.26 
Median (IQR) 0.76 (0.47-0.82) 0.82(0.57-0.89) - 0.16 
Urinary incontinence burden 0 (best) to 10 (worst) 
Mean (SD) 6.2 (3.3) 3.3 (3.4) -2.9 (1.6-4.2) <0.0001 
Median (IQR) 7.0 (3.0-9.0) 3.0 (0-5.5) - <0.0001 
Rockwood faecal incontinence quality of life scale (FIQL) 0 (worst) to 4 (best) 
Lifestyle (0-4) 
Mean (SD) 2.38 (0.76) 3.44 (0.62) 1.06 (0.71-1.41) <0.0001 
Median (IQR) 2.35 (1.78-2.81) 3.55(3.08-3.90) - <0.0001 
Coping (0-4) 
Mean (SD) 1.57 (0.47) 2.79 (0.78) 1.22 (0.89-1.55) <0.0001 
Median (IQR) 1.56 (1.11-1.92) 2.79 (2.40-3.4) - <0.0001 
Depression (0-4) 
Mean (SD) 2.89 (0.90) 3.55 (0.79) 0.67 (0.38-0.95) <0.0001 
Median (IQR) 3.0 (2.25-3.63) 4.0 (3.07-4.17) - <0.0001 
Embarrassment (0-4) 
Mean (SD) 1.77 (0.67) 3.03 (0.99) 1.26 (0.89-1.62) <0.0001 
Median (IQR) 1.67 (1.33-2.08) 3.33 (2.0-3.75) - <0.0001 
 
Table 11 Primary and secondary outcomes from baseline to 12 months (Paper III). Mean (SD), 














ST.MARKS'S SCORE Dato . .
Sykehuset Østfold (100) Ahus (200) Haukeland (300) St. Olav (400) UNN (500) Hvidovre (600)
Lekkasje av fast avføring 0 1 2 3 4
Lekkasje av flytende avføring 0 1 2 3 4
Lekkasje av luft 0 1 2 3 4
Endring av livsstil 0 1 2 3 4



























ICIQ‐UI Dato . .









































SEKSUALFUNKSJON Dato . .
Sykehuset Østfold (100) Ahus (200) Haukeland (300) St. Olav (400) UNN (500) Hvidovre (600)

































BESKRIVELSE AV GENERELL HELSETILSTAND (FIQL) Dato . .
Sykehuset Østfold (100) Ahus (200) Haukeland (300) St. Olav (400) UNN (500) Hvidovre (600)
Spørsmål 1:       Generelt vil du si at din helse er:
1   Utmerket 2   Veldig god 3   God 4   Nokså god 5   Dårlig
Snu




b. Jeg unngår å besøke venner 1 2 3 4
c. Jeg unngår å overnatte hjemmefra 1 2 3 4
d. Det er vanskelig for meg å gå ut og gjøre ting som å gå 1 2 3 4
e. Jeg spiser mindre før jeg går ut 1 2 3 4
f. Når jeg er hjemmefra, prøver jeg å holde meg i nærheten 1 2 3 4
g. Det er viktig at jeg planlegger timeplanen min (daglige 1 2 3 4
h. Jeg unngår å reise 1 2 3 4
i. Jeg bekymrer meg for å ikke nå frem til toalettet i tide 1 2 3 4
j. Jeg føler at jeg ikke har noen kontroll over avføringen min 1 2 3 4
k. Jeg kan ikke holde meg lenge nok til at jeg rekker frem 1 2 3 4
l. Jeg lekker avføring uten at jeg merker det 1 2 3 4























Sykehuset Østfold (100) Ahus (200) Haukeland (300) St. Olav (400) UNN (500) Hvidovre (600)




b. Jeg kan ikke gjøre mange av de tingene jeg har lyst til 1 2 3 4
c. Jeg bekymrer meg for lekkasjeepisoder 1 2 3 4
d. Jeg føler meg deprimert 1 2 3 4
e. Jeg bekymrer meg for at andre skal kjenne avføringslukt 1 2 3 4
f. Jeg føler meg ikke som en frisk person 1 2 3 4
g. Jeg har mindre glede av livet 1 2 3 4
h. Jeg har sjeldnere sex enn det jeg har lyst til å ha 1 2 3 4
i. Jeg føler meg annerleders enn andre mennesker 1 2 3 4
j. Muligheten for lekkasje fra endretarmen er alltid i 1 2 3 4
k. Jeg er redd for å ha sex 1 2 3 4
l. Jeg unngår å reise med fly eller tog 1 2 3 4
m. Jeg unngår å gå ut og spise på resturant 1 2 3 4
Spørsmål 3:
På grunn av uhell med lekkasje fra endetarmen Enig Litt enig Litt uenig Uenig
Ikke
relevant





























BESKRIVELSE AV GENERELL HELSETILSTAND (EQ‐5D) Dato . .



























































Sykehuset Østfold (100) Ahus (200) Haukeland (300) St. Olav (400) UNN (500) Hvidovre (600)
Baseline 3 mnd 6 mnd 12 mnd Kontroll (ekstra)
40730
